A Phase 4 interventional study of liraglutide and alpha-glucosidase inhibitors in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 232 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-07.
Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 12 that started in 2016, is one of 48 in phase 4, and was the 115th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 12 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,991 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 13th largest by enrollment of the 428 interventional ones that give a count, is one of 20 that started in 2016, is one of 75 in phase 4, and was the 412th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs. OADs as add-on to metformin background treatment for 104 weeks of treatment in subjects with type 2 diabetes.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 1,991 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: - Male or female at least 18 years of age at the time of signing - Subjects diagnosed (clinically) with type 2 diabetes equal to or above 90 days prior to the screening visit - Stable daily dose of metformin as monotherapy equal to or above 1500 mg or maximum tolerated dose within 60 days prior to the screening visit - 7.5-9.0% (59-75 mmol/mol) (both inclusive) and measured within the last 90 days prior to the screening visit Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate methods (adequate contraceptive measures as required by local regulation or practice) - Treatment with any medication for the indication of diabetes other than metformin in a period of 60 days before the screening visit. An exception is short-term treatment (below or equal to 7 days in total) with insulin in connection with intercurrent illness - Receipt of any medicinal product within 30 days before the screening visit - Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Add-on to metformin
Drug: liraglutide
Add-on to metformin. Treatment with one OAD selected at the discretion of the investigator. Subjects randomised to the OAD arm must remain on the same OAD throughout the trial.
Drug: alpha-glucosidase inhibitors · Drug: DPP-4 inhibitors · Drug: meglitinides · Drug: SGLT-2 inhibitors · Drug: sulphonylurea · Drug: thiazolidinediones
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Time to Inadequate Glycaemic Control
Inadequate glycaemic control was defined as glycosylated haemoglobin (HbA1c) of 7.0% (53 mmol/mol) or greater at two consecutive visits after the first 26 weeks of treatment and up to 104 weeks. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function. HbA1c was recorded at weeks 38, 52, 65, 78, 91 and 104.
Time frame: Weeks 26-104
Time to Premature Treatment Discontinuation (for Any Reason Including Inadequate Glycaemic Control)
The time to premature treatment discontinuation (for any reason including inadequate glycaemic control) was analysed and presented using the generalised log rank test. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function.
Time frame: Weeks 0-104
Change in HbA1c
Change from baseline (week 0) in HbA1c at week 104 or at premature treatment discontinuation is presented.
Time frame: Week 0, week 104/premature treatment discontinuation
Participants Who Achieve HbA1c ≤6.5% (Yes/No)
Participants who achieved HbA1c ≤6.5% (yes/no) is presented.
Time frame: Week 104/Premature treatment discontinuation
Participants Who Achieve HbA1c ≤7.0% Without Weight Gain
Participants who achieved HbA1c ≤7.0% without weight gain (yes/no) is presented.
Time frame: Week 104/Premature treatment discontinuation
Participants Who Achieve HbA1c ≤7.0% Without Treatment Emergent Severe Hypoglycaemic Episodes or BG Confirmed Symptomatic Hypoglycaemic Episodes
Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 millimoles per liter (mmol/L) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented.
Time frame: Week 104/Premature treatment discontinuation
Participants Who Achieve HbA1c ≤7.0% Without Weight Gain and no Treatment Emergent Severe Hypoglycaemic Episodes or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes
Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without weight gain and no treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented.
Time frame: Week 104/Premature treatment discontinuation
Change in Fasting Plasma Glucose (FPG)
Change from baseline (week 0) in FPG at week 104 or at premature treatment discontinuation is presented.
Time frame: Week 0, week 104/premature treatment discontinuation
Change in Body Weight
Change from baseline (week 0) in body weight at week 104 or at premature treatment discontinuation is presented.
Time frame: Week 0, week 104/premature treatment discontinuation
Change in Body Mass Index (BMI)
Change from baseline (week 0) in BMI at week 104 or at premature treatment discontinuation is presented.
Time frame: Week 0, week 104/premature treatment discontinuation
Change in Blood Pressure (Systolic and Diastolic Blood Pressure)
Change from baseline (week 0) in systolic and diastolic blood pressure at week 104 or at premature treatment discontinuation is presented.
Time frame: Week 0, week 104/premature treatment discontinuation
Number of Severe Hypoglycaemic Episodes
Severe hypoglycaemic episodes were defined as episodes that required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Number of severe hypoglycaemic episodes that occured during weeks 0-104 are presented.
Time frame: Weeks 0-104
Number of Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Number of severe or BG confirmed symptomatic hypoglycaemic episodes that occured during weeks 0-104 are presented.
Time frame: Weeks 0-104
Number of Documented Symptomatic Hypoglycaemic Episodes (ADA)
Documented symptomatic hypoglycaemic were defined as episodes with typical symptoms of hypoglycaemia accompanied by measure plasma glucose concentration \<= 3.9 mmol/L. Number of documented symptomatic hypoglycaemic episodes that occured during the weeks 0-104 are presented.
Time frame: Weeks 0-104
Number of Serious Adverse Events (SAEs)
A serious adverse event (SAE) was defined as any event that resulted in any of the following: death, life-threatening experience, in-patient hospitalisation or prolongation of existing hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect or suspicion of transmission of infectious agents via the trial product. An SAE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent serious adverse events are presented.
Time frame: Weeks 0-105
Number of AEs Leading to Permanent Discontinuation of Trial Product
An adverse event (AE) was any untoward medical occurrence in a participant who administered a product, and which did not necessarily had a causal relationship with this treatment. An AE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent AEs that led to permanent discontinuation of trial product are presented.
Time frame: Weeks 0-105
Change in Lipids: HDL Cholesterol, LDL-cholesterol, Total Cholesterol, Triglycerides
Change from baseline (week 0) in high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol (TC) and triglycerides (TG) at week 104 or at premature treatment discontinuation is presented.
Time frame: Week 0, week 104/premature treatment discontinuation
Change in Biochemistry- Alanine Aminotransferase (ALAT), Amylase, Aspartate Aminotransferase (ASAT), Lipase
Change from baseline (week 0) in alanine aminotransferase (ALAT), amylase, aspartate aminotransferase (ASAT) and lipase at week 104 or at premature treatment discontinuation is presented.
Time frame: Week 0, week 104/premature treatment discontinuation
Change in Biochemistry- Creatinine, Total Bilirubin
Change from baseline (week 0) in creatinine and total bilirubin (TB) at week 104 or at premature treatment discontinuation is presented.
Time frame: Week 0, week 104/premature treatment discontinuation
Change in Biochemistry- Estimated Glomerular Filtration Rate (eGFR) Serum
The estimated GFR was derived from serum creatinine using the MDRD (Modification of diet in renal disease) formula. eGFR was measured as milliliter per min per specific surface area (mL/min/SSA).
Time frame: Week 0, week 104/premature treatment discontinuation
Change in Potassium
Change from baseline (week 0) in potassium at week 104 or at premature treatment discontinuation is presented.
Time frame: Week 0, week 104/premature treatment discontinuation
Change in Haemoglobin
Change from baseline (week 0) in haemoglobin at week 104 or at premature treatment discontinuation is presented.
Time frame: Week 0, week 104/premature treatment discontinuation
Change in Pulse
Change from baseline (week 0) in pulse at week 104 or at premature treatment discontinuation is presented.
Time frame: Week 0, week 104/premature treatment discontinuation
The trial was conducted at 219 sites in Canada (11), Colombia (3), India (16), Latvia (2), Lebanon (4), Russian Federation (5), Serbia (6), Turkey (4) and the United States (168).
| Milestone | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Started | 996 | 995 |
| Treated | 980 | 984 |
| Full analysis set (fas) | 996 | 995 |
| Safety analysis set (sas) | 980 | 984 |
| Completed | 446 | 362 |
| Not completed | 550 | 633 |
| Withdrew: Other | 5 | 4 |
| Withdrew: Death | 1 | 8 |
| Withdrew: Inadequate glycaemic control | 368 | 473 |
| Withdrew: Adverse event | 79 | 41 |
| Withdrew: Protocol violation | 23 | 30 |
| Withdrew: Lack of efficacy | 4 | 13 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Withdrawal by subject | 45 | 42 |
| Withdrew: Lost to follow-up | 25 | 21 |
Inadequate glycaemic control was defined as glycosylated haemoglobin (HbA1c) of 7.0% (53 mmol/mol) or greater at two consecutive visits after the first 26 weeks of treatment and up to 104 weeks. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function. HbA1c was recorded at weeks 38, 52, 65, 78, 91 and 104.
| Weeks | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Time to Inadequate Glycaemic Control | 108.9 (37.7 to NA) | 64.9 (35.4 to 107.4) |
The time to premature treatment discontinuation (for any reason including inadequate glycaemic control) was analysed and presented using the generalised log rank test. 25%, median (50%) and 75% percentiles for the cumulative distribution function, are obtained from the Kaplan-Meier survival function.
| Weeks | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Time to Premature Treatment Discontinuation (for Any Reason Including Inadequate Glycaemic Control) | 80.4 (35.7 to NA) | 52.3 (35.1 to NA) |
Change from baseline (week 0) in HbA1c at week 104 or at premature treatment discontinuation is presented.
| Percentage point of HbA1c | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Change at week 104 | -1.4 ± 1.06 | -1.1 ± 1.04 |
| Change at premature treatment discontinuation | -0.6 ± 1.03 | -0.2 ± 1.56 |
Participants who achieved HbA1c ≤6.5% (yes/no) is presented.
| Participants | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Yes | 255 | 162 |
| No | 741 | 833 |
Participants who achieved HbA1c ≤7.0% without weight gain (yes/no) is presented.
| Participants | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Yes | 329 | 234 |
| No | 667 | 761 |
Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 millimoles per liter (mmol/L) with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented.
| Participants | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Yes | 388 | 292 |
| No | 608 | 703 |
Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than the day after the last day on trial product. Participants who achieved HbA1c ≤7.0% without weight gain and no treatment emergent severe hypoglycaemic episodes or BG confirmed symptomatic hypoglycaemic episodes (yes/no) is presented.
| Participants | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Yes | 320 | 227 |
| No | 676 | 768 |
Change from baseline (week 0) in FPG at week 104 or at premature treatment discontinuation is presented.
| Millimoles per liter (mmol/L) | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Change at week 104 | -2.2 ± 2.65 | -1.2 ± 2.46 |
| Change at premature treatment discontinuation | -0.6 ± 2.91 | -0.6 ± 3.76 |
Change from baseline (week 0) in body weight at week 104 or at premature treatment discontinuation is presented.
| Kilogram (Kg) | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Change at week 104 | -3.8 ± 6.38 | -3.5 ± 6.19 |
| Change at premature treatment discontinuation | -2.9 ± 3.74 | -2.2 ± 4.93 |
Change from baseline (week 0) in BMI at week 104 or at premature treatment discontinuation is presented.
| Kilograms per square meter (kg/m^2) | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Change at week 104 | -1.3 ± 2.26 | -1.2 ± 2.14 |
| Change at premature treatment discontinuation | -1.1 ± 1.33 | -0.8 ± 1.71 |
Change from baseline (week 0) in systolic and diastolic blood pressure at week 104 or at premature treatment discontinuation is presented.
| Millimeters of mercury (mmHg) | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| SBP: Change at week 104 | -2.4 ± 15.09 | -1.1 ± 15.11 |
| SBP: Change at premature treatment discontinuation | -2.8 ± 15.99 | -2.9 ± 15.23 |
| DBP: Change at week 104 | -1.3 ± 9.51 | -0.6 ± 9.54 |
| DBP: Change at premature treatment discontinuation | -1.0 ± 11.27 | 0.2 ± 9.69 |
Severe hypoglycaemic episodes were defined as episodes that required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Number of severe hypoglycaemic episodes that occured during weeks 0-104 are presented.
| Episodes | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Number of Severe Hypoglycaemic Episodes | 32 | 52 |
Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Number of severe or BG confirmed symptomatic hypoglycaemic episodes that occured during weeks 0-104 are presented.
| Episodes | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Number of Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes | 24 | 44 |
Documented symptomatic hypoglycaemic were defined as episodes with typical symptoms of hypoglycaemia accompanied by measure plasma glucose concentration \<= 3.9 mmol/L. Number of documented symptomatic hypoglycaemic episodes that occured during the weeks 0-104 are presented.
| Episodes | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Number of Documented Symptomatic Hypoglycaemic Episodes (ADA) | 98 | 155 |
A serious adverse event (SAE) was defined as any event that resulted in any of the following: death, life-threatening experience, in-patient hospitalisation or prolongation of existing hospitalisation, persistent or significant disability or incapacity, congenital anomaly or birth defect or suspicion of transmission of infectious agents via the trial product. An SAE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent serious adverse events are presented.
| Events | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Number of Serious Adverse Events (SAEs) | 145 | 140 |
An adverse event (AE) was any untoward medical occurrence in a participant who administered a product, and which did not necessarily had a causal relationship with this treatment. An AE was considered as treatment emergent if it had an onset or increase in severity on or after the time of first trial product administration and no later than 7 days after the time of last trial product administration. Number of treatment emergent AEs that led to permanent discontinuation of trial product are presented.
| Events | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Number of AEs Leading to Permanent Discontinuation of Trial Product | 188 | 98 |
Change from baseline (week 0) in high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol (TC) and triglycerides (TG) at week 104 or at premature treatment discontinuation is presented.
| Millimoles per liter (mmol/L) | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| HDL: Change at week 104 | 0.1 ± 0.20 | 0.1 ± 0.19 |
| HDL: Change at premature treatment discontinuation | -0.0 ± 0.17 | 0.0 ± 0.20 |
| LDL: Change at week 104 | -0.1 ± 0.80 | 0.0 ± 0.83 |
| LDL: Change at premature treatment discontinuation | -0.1 ± 0.68 | -0.1 ± 0.85 |
| TC: Change at week 104 | -0.2 ± 0.92 | 0.1 ± 0.99 |
| TC: Change at premature treatment discontinuation | -0.0 ± 0.81 | -0.1 ± 0.96 |
| TG: Change at week 104 | -0.3 ± 0.95 | -0.1 ± 1.25 |
| TG: Change at premature treatment discontinuation | -0.0 ± 1.13 | -0.0 ± 1.30 |
Change from baseline (week 0) in alanine aminotransferase (ALAT), amylase, aspartate aminotransferase (ASAT) and lipase at week 104 or at premature treatment discontinuation is presented.
| Units per liter (U/L) | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| ALAT: Week 104 | -4.6 ± 17.83 | -5.4 ± 17.13 |
| ALAT: Premature treatment discontinuation | -3.2 ± 12.44 | -3.3 ± 14.67 |
| Amylase: Week 104 | 8.9 ± 30.93 | 5.1 ± 26.30 |
| Amylase: Premature treatment discontinuation | 0.6 ± 23.61 | 2.1 ± 17.92 |
| ASAT: Week 104 | -2.0 ± 13.27 | -2.3 ± 11.85 |
| ASAT: Premature treatment discontinuation | -1.9 ± 10.76 | -0.4 ± 11.64 |
| Lipase: Week 104 | 15.1 ± 67.69 | -0.5 ± 50.03 |
| Lipase: Premature treatment discontinuation | 10.4 ± 32.40 | -2.2 ± 35.79 |
Change from baseline (week 0) in creatinine and total bilirubin (TB) at week 104 or at premature treatment discontinuation is presented.
| Micromoles per liter (umol/L) | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Creatinine: week 104 | 3.3 ± 13.37 | 1.0 ± 12.86 |
| Creatinine: premature treatment discontinuation | 2.9 ± 12.06 | 2.6 ± 21.13 |
| TB: week 104 | 0.4 ± 4.47 | 0.7 ± 3.80 |
| TB: premature treatment discontinuation | -0.0 ± 2.78 | -0.6 ± 3.17 |
The estimated GFR was derived from serum creatinine using the MDRD (Modification of diet in renal disease) formula. eGFR was measured as milliliter per min per specific surface area (mL/min/SSA).
| mL/min/SSA | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Change at week 104 | -5.1 ± 20.33 | -1.6 ± 16.29 |
| Change at premature treatment discontinuation | -3.0 ± 12.56 | -1.7 ± 15.01 |
Change from baseline (week 0) in potassium at week 104 or at premature treatment discontinuation is presented.
| Millimoles per liter (mmol/L) | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Change at week 104 | -0.1 ± 0.60 | -0.0 ± 0.59 |
| Change at premature treatment discontinuation | -0.0 ± 0.44 | -0.2 ± 0.71 |
Change from baseline (week 0) in haemoglobin at week 104 or at premature treatment discontinuation is presented.
| Grams per deciliter (g/dL) | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Change at week 104 | -0.4 ± 1.07 | -0.0 ± 1.16 |
| Change at premature treatment discontinuation | -0.3 ± 0.87 | -0.3 ± 1.12 |
Change from baseline (week 0) in pulse at week 104 or at premature treatment discontinuation is presented.
| Beats per minute (beats/min) | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Change at week 104 | 1.0 ± 10.25 | -0.6 ± 10.23 |
| Change at premature treatment discontinuation | 0.7 ± 9.84 | 0.9 ± 10.59 |
Collected over Weeks 0-105. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide 1.8 mg | 1/980 (0.1%) | 92/980 (9.4%) | 65/980 (6.6%) |
| Oral Antidiabetic Drug | 8/984 (0.8%) | 81/984 (8.2%) | 15/984 (1.5%) |
| Event | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 6/980 | 2/984 |
| Acute myocardial infarctionCardiac disorders | 5/980 | 6/984 |
| PneumoniaInfections and infestations | 4/980 | 5/984 |
| Angina pectorisCardiac disorders | 4/980 | 1/984 |
| Cerebrovascular accidentNervous system disorders | 4/980 | 1/984 |
| Chest painGeneral disorders | 4/980 | 1/984 |
| Cardiac failure congestiveCardiac disorders | 3/980 | 4/984 |
| Atrial fibrillationCardiac disorders | 3/980 | 2/984 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 3/980 | 1/984 |
| SepsisInfections and infestations | 0/980 | 3/984 |
| Event | Liraglutide 1.8 mg | Oral Antidiabetic Drug |
|---|---|---|
| NauseaGastrointestinal disorders | 65/980 | 15/984 |
FAS included all randomised participants.
| Age, Continuous(Years) | Liraglutide 1.8 mg | Oral Antidiabetic Drug | Total |
|---|---|---|---|
| Mean | 57.6 ± 11.0 | 57.1 ± 10.7 | 57.4 ± 10.8 |
| Sex: Female, Male(Participants) | Liraglutide 1.8 mg | Oral Antidiabetic Drug | Total |
|---|---|---|---|
| Female | 476 | 471 | 947 |
| Male | 520 | 524 | 1044 |
| Ethnicity (NIH/OMB)(Participants) | Liraglutide 1.8 mg | Oral Antidiabetic Drug | Total |
|---|---|---|---|
| Hispanic or Latino | 176 | 189 | 365 |
| Not Hispanic or Latino | 820 | 806 | 1626 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Liraglutide 1.8 mg | Oral Antidiabetic Drug | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 6 | 9 |
| Asian | 149 | 141 | 290 |
| Black or African American | 101 | 106 | 207 |
| Native Hawaiian or Other Pacific Islander | 3 | 2 | 5 |
| White | 724 | 714 | 1438 |
| Other | 16 | 26 | 42 |
Showing the first 100 of 232 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Ran from Mar 2016 to primary completion in Aug 2019, 40 months.
Results were first posted in Jul 2020, 11 months after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 40 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide